Blas Rituxan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.

United statesEpogen procritBlas rituxanHuman servicesDrug administrationOrange bookPurple bookBiologics price competitionInnovation actHatch waxman actBiosimilars actBiologics license applicationNew drug applicationsAbbreviated new drug applicationsPurple book continuity actContinuity act